A Phase 2a Multicenter Randomized Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderate to Severe Crohn's Disease

Go Back to All Clinical Trials

A Phase 2a Multicenter Randomized Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderate to Severe Crohn's Disease

Brief description of study

The purpose of this study is to evaluate the safety and efficacy of using multiple investigational medicines compared to a single medicine in subjects with moderate to severe Crohn’s Disease. The medicines being used in this study are Risankizumab, ABBV-382, and Lutikizumab.

Clinical Study Identifier: s24-00386

ClinicalTrials.gov Identifier: NCT06548542

Principal Investigator: Lev Ginzburg.

Other Investigators: Blanche Fung Liu, Seymour Katz.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies